Fulgent Genetics宣布Fid-007头颈癌研究完整摘要将于ASCO 2026年会头颈癌专题会议进行快速口头报告

美股速递
May 22

Fulgent Genetics公司宣布,其研究性药物Fid-007针对头颈癌的完整研究摘要,已被选定于2026年美国临床肿瘤学会(ASCO)年会头颈癌专题会议中进行快速口头报告。

这一安排标志着该研究获得了国际顶级肿瘤学会议的高度关注,其数据将在这一全球肿瘤学界的盛会上进行正式展示与交流。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10